AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tonyt who wrote (534)	8/19/1997 10:25:00 PM
From: Cacaito	of 2173

tonyt, I was clear: 1. Maybe they expect better results from the ongoing studies, and this is already paid for, so it is not much more further expenses. 2. I said: maybe they are interested in other aspects of AMLN business ,like the recent agreement with two other biotechs (visit Amylin web site and you can find the specifics. 3. Amylin web site is clear: J&J will share profits and losses. 4. and I do not like Vector Secs and I was clear to state that this is my personal bias, maybe they are good at what they do (Vector, I mean) 5. Besides, I do not even think that they had a poorly design study, they have a very good study with a poor outcome in many respects. They are quite honest in not trying to interpret the findings with recalculations after the facts ( like ABTI did ). They just redesign the ongoing studies (which I said it could be very expensive, and always time consuming, and always delay datelines). 6. I would love to see Amylin the drug to be a success, I had take care of Type I DM in children and I wish for then the best research can offer. 7. I came to see this thread after the Friday release. So far I do not hold any shares.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next